Therefore, we speculate that the decrease in CCL2 observed in our patients with end-stage ALD may be due to cirrhosis-related fat loss, and that this reduction might be less pronounced in GG carriers due to impaired lipid metabolism. Here, CCL2 is linked to Cirrhosis.